Literature DB >> 8646974

[Catheter treatment of hypertrophic obstructive cardiomyopathy].

U Gleichmann1, H Seggewiss, L Faber, D Fassbender, H K Schmidt, S Strick.   

Abstract

BASIC PROBLEMS AND
OBJECTIVE: In addition to medication with negative inotropic drugs, surgical myectomy and DDD pacemaker implantation are standard procedures in the treatment of hypertrophic obstructive cardiomyopathy (HOCM). In a preliminary series the results obtained with a recently described method, consisting of transcatheter myocardial reduction, are evaluated. PATIENTS AND METHODS: Six patients (two women, four men; mean age 52.7 [44-68] years), who remained in moderate heart failure despite medical treatment, underwent the procedure. After atrial transseptal puncture (via a catheter introduced percutaneously into the femoral vein) the left ventricular outflow tract (LVOT) gradient was measured at rest and after 5-minute balloon occlusion of the first septal branch of the left coronary artery. After demonstration of significant reduction of the gradient by the occlusion, one (n = 3) or two (n = 3) septal branches were occluded by the injection of 2-5 ml of 96% alcohol.
RESULTS: The LVOT gradient was reduced from 57.8 +/- 22.4 (38-97) mm Hg to 11.3 +/- 8.6 (0-21) mm Hg and postextrasystolic from 131.0 +/- 40.7 (78-198) mm Hg to 44.0 +/- 35.6 (19-69) mm Hg. All patients had angina for 24 hours after the procedure. Maximal rise in creatine kinase activity was 982 +/- 589 (392-1729) U/l after 8.0 +/- 3.9 (4-15) hours. In three patients transitory complete atrioventricular block developed 10 min to 5 days later, requiring temporary pacemaker implantation. The further course was without complication in all patients and they were discharged after 7.5 +/- 1.8 (6-11) days.
CONCLUSION: The described catheter method provides a nonsurgical means of reducing the amount of septal myocardium with subsequent reduction of the LVOT gradient in HOCM. Long-term observation in a larger group of patients and comparison with conventional forms of treatment are required to determined the method's ultimate place in the treatment of HOCM.

Entities:  

Mesh:

Year:  1996        PMID: 8646974     DOI: 10.1055/s-2008-1043055

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  6 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

2.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.

Authors:  L Faber; A Meissner; P Ziemssen; H Seggewiss
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

Review 3.  Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelika Batzner; Hans-Joachim Schäfers; Konstantin V Borisov; Hubert Seggewiß
Journal:  Dtsch Arztebl Int       Date:  2019-01-25       Impact factor: 5.594

4.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

Review 5.  [Syncope in hypertrophic (obstructive) cardiomyopathy].

Authors:  Hubert Seggewiß; Angelika Koljaja-Batzner; Kornelia Seggewiß; Malte Meesmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

Review 6.  [Clinical picture and therapy of hypertrophic cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss
Journal:  Med Klin (Munich)       Date:  1998-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.